Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer
出版年份 2020 全文链接
标题
Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer
作者
关键词
-
出版物
Journal for ImmunoTherapy of Cancer
Volume 8, Issue 2, Pages e000698
出版商
BMJ
发表日期
2020-08-06
DOI
10.1136/jitc-2020-000698
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- PD-1 Ligand Expression in Epithelial Thyroid Cancers: Potential Clinical Implications
- (2019) Salvatore Ulisse et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
- (2019) Paolo Antonio Ascierto et al. NATURE MEDICINE
- Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
- (2019) Antoni Ribas et al. NATURE MEDICINE
- Enhanced Therapeutic Efficacy of a Novel Oncolytic Herpes Simplex Virus Type 2 Encoding an Antibody Against Programmed Cell Death 1
- (2019) Yujie Zhu et al. Molecular Therapy-Oncolytics
- Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
- (2018) Frederick Arce Vargas et al. CANCER CELL
- Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression
- (2018) Heng Lin et al. JOURNAL OF CLINICAL INVESTIGATION
- PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression
- (2018) Haidong Tang et al. JOURNAL OF CLINICAL INVESTIGATION
- Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer
- (2018) Vivek Subbiah et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunological effects of BRAF+MEK inhibition
- (2018) Paolo A. Ascierto et al. OncoImmunology
- Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma
- (2018) Priyanka C. Iyer et al. Journal for ImmunoTherapy of Cancer
- Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer
- (2018) Viswanath Gunda et al. BRITISH JOURNAL OF CANCER
- Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer
- (2018) Viswanath Gunda et al. INTERNATIONAL JOURNAL OF CANCER
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation
- (2018) Praveen K. Bommareddy et al. Science Translational Medicine
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exceptional Response with Immunotherapy in a Patient with Anaplastic Thyroid Cancer
- (2017) Revathi Kollipara et al. ONCOLOGIST
- Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer
- (2016) Adel Samson et al. GUT
- BRAF Inhibition inBRAFV600E-Positive Anaplastic Thyroid Carcinoma
- (2016) Annette M. Lim et al. Journal of the National Comprehensive Cancer Network
- Sustained Response to Vemurafenib in aBRAFV600E-Mutated Anaplastic Thyroid Carcinoma Patient
- (2016) Gerald W. Prager et al. THYROID
- BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients
- (2016) Langping Jin et al. Oncotarget
- Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer
- (2016) Eran Brauner et al. Oncotarget
- Treatment of Human Thyroid Carcinoma Cells with the G47delta Oncolytic Herpes Simplex Virus
- (2015) Jia-Ni Wang et al. Asian Pacific Journal of Cancer Prevention
- Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
- (2015) Maria Romina Girotti et al. CANCER CELL
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
- (2015) David M. Hyman et al. NEW ENGLAND JOURNAL OF MEDICINE
- limma powers differential expression analyses for RNA-sequencing and microarray studies
- (2015) Matthew E. Ritchie et al. NUCLEIC ACIDS RESEARCH
- Association of oncolytic adenoviruses with chemotherapies: An overview and future directions
- (2014) Christian Bressy et al. BIOCHEMICAL PHARMACOLOGY
- Human Anaplastic Thyroid Carcinoma Cells Are Sensitive to NK Cell-Mediated Lysis via ULBP2/5/6 and Chemoattract NK Cells
- (2014) E. Wennerberg et al. CLINICAL CANCER RESEARCH
- p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer
- (2014) D. G. McFadden et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- (2013) D. T. Frederick et al. CLINICAL CANCER RESEARCH
- Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer
- (2013) Mingzhao Xing et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- BRAF V600E Inhibition in Anaplastic Thyroid Cancer
- (2013) Michael H. Rosove et al. NEW ENGLAND JOURNAL OF MEDICINE
- Capacity of wild-type and chemokine-armed parvovirus H-1PV for inhibiting neo-angiogenesis
- (2013) Muriel Lavie et al. VIROLOGY
- NanoStringNorm: an extensible R package for the pre-processing of NanoString mRNA and miRNA data
- (2012) Daryl Waggott et al. BIOINFORMATICS
- BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
- (2012) C. Liu et al. CLINICAL CANCER RESEARCH
- BRAF inhibition improves tumor recognition by the immune system
- (2012) Marco Donia et al. OncoImmunology
- Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
- (2011) James S. Wilmott et al. CLINICAL CANCER RESEARCH
- BRAFV600E Mutation is Associated with Tumor Aggressiveness in Papillary Thyroid Cancer
- (2011) Su-jin Kim et al. WORLD JOURNAL OF SURGERY
- Phase I/II Study of Oncolytic HSVGM-CSF in Combination with Radiotherapy and Cisplatin in Untreated Stage III/IV Squamous Cell Cancer of the Head and Neck
- (2010) K. J. Harrington et al. CLINICAL CANCER RESEARCH
- Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice
- (2009) Nathalie Dhomen et al. CANCER CELL
- Synergy of a Herpes Oncolytic Virus and Paclitaxel for Anaplastic Thyroid Cancer
- (2008) S.-F. Lin et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now